Mesenchymal stem cells enchanced by salidroside to inhibit ferroptosis and improve premature ovarian insufficiency via Keap1/Nrf2/GPX4 signaling

Background Regenerative medicine researches have shown that mesenchymal stem cells (MSCs) may be an effective treatment method for premature ovarian insufficiency (POI). However, the efficacy of MSCs is still limited.Purpose This study aims to explain whether salidroside and MSCs combination is a th...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Lixuan Chen, Yingnan Wu, Tiying Lv, Rui Tuo, Yang Xiao
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Taylor & Francis Group 2025-12-01
Sarja:	Redox Report
Aiheet:	Salidroside mesenchymal stem cells premature ovarian insufficiency ferroptosis Keap1/Nrf2/GPX4 signaling ‌redox homeostasis
Linkit:	https://www.tandfonline.com/doi/10.1080/13510002.2025.2455914
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!